Call Us: 800.647.6100
  • US
    • Canada

People-First Culture

XYMOGEN thrives on its culture of strong customer service, personal excellence, high energy, and the true enjoyment of helping people improve their health.

People-First Culture

About Us

When you partner with XYMOGEN, you not only receive the-highest quality formulas in the practitioner channel; you also get the support of our long-standing functional medicine consultant team, as well as the best customer service in the industry. Why? Simple: Because we care. We care about the fact that you want to help people live their healthiest. We care that you want safe, effective formulas on which you can rely. We are a team, helping to bring patients what they are searching for — better health and wellness.

Manufacturing

The Journey Is the Reward
XYMOGEN Exclusive Professional Formulas has over a quarter century of experience providing quality supplements to healthcare practitioners. As an independent health sciences company, XYMOGEN has introduced numerous innovations to the functional medicine community. From the beginning, "the journey is the reward" has been our mantra. It is a journey that offers unprecedented opportunities for growth and fulfillment.

XYMOGEN HQ

XYMOGEN’s Core Principle: People-First 

XYMOGEN is proud of our "People-First" culture. We can only achieve continued success and growth by staying tenaciously committed to these five principles:

  • Creating a dynamic, open corporate environment that encourages a team approach to problem solving, new product development and industry first initiatives.
  • Establishing an inverted pyramid organizational structure where the first priority of all leaders is to ensure every team member knows that their thoughts and opinions are encouraged and valued.
  • Providing resources, education and training for team members to maximize their highest potential so that they may move up in our company and find career satisfaction.
  • Encouraging fitness, health and to make time for play by offering team members access to our 24/7, no-fee exercise facilities, which includes a basketball/volleyball court as well as a fitness center with treadmills and weights.
  • Attracting the most talented, fun and motivated people from many different backgrounds to our winning team through a variety of avenues, including relationship building with the scores of professionals who have maximized their health through our formulas and our already established team of diverse and deeply devoted team members.

 


XYMOGEN History

In October of 2003, the nutraceutical company XYMOGEN was created. Since that time, XYMOGEN has shown considerable growth with more than a decade of continued success. The company has repeatedly outgrown offices, necessitating the construction in 2012 of a new, state-of-the-art manufacturing facility. It has also developed its own lucrative private labeling program, launched the subsidiary company Labels in Motion, and gone from a distributorship to a supplement manufacturer. Here’s to the future, with even more success to come.

Passion + Commitment = Growth
Our commitment to quality, our commitment to our practitioners, and a passion for natural healthcare allow us to keep growing. Our team mentality, quarterly product pipeline launches, continuing education events, customer recognition programs, and international expansion also contribute to our continued ability to rise above the competition. XYMOGEN’s strength as a company has been reinforced repeatedly. XYMOGEN has recently been recognized for the ninth time on Inc. Magazine’s Inc. 5000 list as one of the fastest growing and best-run private companies in the nation.  XYMOGEN joined the “Honor Roll Alumni” in 2012, which is the elite group of companies who have made the list at least five times. They have now appeared nine times in the last ten years, putting them among only five percent of the current 5000 honorees to be featured nine or more times.

Partnership with Dr. David Perlmutter, FACN, ABIHM
In February 2010, XYMOGEN acquired Dr. David Perlmutter’s iNutritionals line of neurological formulas. The addition of BrainSustain™ and NeuroActives™ BrainSustain™ to the XYMOGEN line positions us as a leader in the modulation of neurological disorders.

XYMOGEN Facility

XYMOGEN proved that there really is no place like home as we opened our new global headquarters in Orlando, FL, in April 2012. The complex’s design strategically weaves an ultramodern manufacturing and packaging system, a merchandise center, full-service research laboratories, a warehouse, marketing studios, a customer service department, digital printing services, and administrative services under one massive roof.

More than 40,000 square feet are dedicated to manufacturing and packaging, and this also includes a 4,000-square-foot full-service laboratory to test all raw materials and goods.

The expanding success of XYMOGEN’s seminar series and tradeshow exhibitions motivated us to include our own conference center in the building. This enables us to host educational programs in the facility year-round.

Our new headquarters was built to LEED (Leadership in Energy and Environmental Design) standards. For a start, it offers “green” features, such as parking spaces dedicated to energy-efficient cars, and there is a non-smoking policy.

From day one, founder Brian Blackburn’s business has been structured around core family values, and a happy and positive workplace. For that reason, the building design also includes spacious work areas, a 24-hour gymnasium, and a basketball court for the more than 150 employees.

The XYMOGEN work environment has always been Brian Blackburn’s first priority. He believes that the successful operation of a business pivots on nurturing and caring for employees. This philosophy continues today.


Investors

Generating Higher Value

Q4 2004 - $7.50

Q4 2005 - $7.50

Q4 2006 - $12.50

Q4 2007 - $15.00

Q4 2008 - $23.65

Q4 2009 - $32.08

Q4 2010 - $42.91

Q4 2011 - $54.15

Q4 2012 - $58.55

Q4 2013 - $71.04

Q4 2014 - $82.25

Q4 2015 - $96.54

Q2 2016 - $103.26


Dear XYMOGEN Partner,

From settling into our new, state-of-the-art headquarters and manufacturing facility to being named one of Inc. magazine’s 5000 fastest-growing private companies for the eighth time, this past year has been both exciting and rewarding. This is a testament to the people, philosophy and culture that continue to make this journey we call XYMOGEN so exciting. We are committed long-term to all team members, customers and investors who have contributed and continue to contribute to our success

What distinguishes XYMOGEN from other nutraceutical companies is our creativity. We are a very creative organization, and we strive to use our creativity in everything we do. I believe that the best way to predict the future is to create it, and our creativity helps us stay ahead of the competition and remain the premier source of nutritional products in the practitioner channel.

As a result of our creative efforts, we have seen overwhelming success in our international expansion and also with our label publishing company, Labels in Motion™. We also plan to introduce numerous innovations in the coming year, including our ePedigree initiative and MedPax™, our science-based approach to personalized nutrition that allows practitioners and patients to create unique, daily supplement packets, designed to replace the patients’ many formula bottles, in addition to numerous other additions and revisions to enhance our formula line.

On behalf of our ever growing XYMOGEN TEAM, I wish you all the best for a healthy, happy, and prosperous journey with us.

Sincerely,

Brian J. Blackburn, CEO

 

Company Overview

XYMOGEN® is a family-owned health sciences company headquartered in Orlando, Florida, that has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community, and its medical board of advisors consists of clinical practitioners who represent a broad range of specialties.


 

Certified Manufacturing Facility

XYMOGEN’s 136,000-square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International. The NSF mark assures consumers, retailers, and regulators that products have been rigorously tested to comply with all standard requirements.


 

Regulations and Inspections

Since October 2015, XYMOGEN has had the unique distinction of being inspected and approved by Australia’s Therapeutic Goods Administration (TGA), the pharmaceutical regulatory agency of Australia. Considered the toughest regulatory agency in the world, the TGA inspection and certification is conducted at a pharmaceutical-level standard. Only a handful of U.S. companies are able to achieve the status of holding a TGA certification.


 

Fastest Growing

XYMOGEN’s strength as a company was reinforced again in 2015, when it was recognized for the eighth time by Inc. magazine  as one of the top 5000 fastest-growing, US-based, private companies in America.

XYMOGEN is fortunate to be in the Practitioner Channel of the Health & Wellness Sector. Over the past five years, this has been among the fastest-growing business sectors in our country. At a time when few companies are growing, as of June 30, 2016, XYMOGEN has grown revenues for 49 consecutive quarters and has realized over 500 percent growth in the past five years. Over this five-year period the share price has grown from $51.17 to $103.26. We believe with our current and planned initiatives the next five years will likely be our best growth period to date.


 

Quarterly Share Price

XYMOGEN’s share price is valued quarterly, and, as of June 30, 2016, the share price is posted to our website with a value of $103.26. The next share valuation, as of September 30, 2016, will be posted to our website on or about October 15, 2016.


KEY PROJECTS

  • Partnership with David Perlmutter, MD: In February 2010, XYMOGEN acquired Dr. David Perlmutter’s iNutritionals line of neurological formulas. The addition of BrainSustain™ and NeuroActives™ BrainSustain™ to the XYMOGEN line positions us as a leader in the modulation of neurological disorders.
  • Quarterly Pipeline Launches: XYMOGEN's continued growth and success allows us to keep expanding and improving our line of formulas in order to meet patients’ health needs. Our quarterly releases of innovative formulas reflect the latest scientific findings in the field of nutritional science as well as feedback from our Medical Board of Advisors and XYMOGEN practitioners worldwide.
  • International Growth: XYMOGEN continues to see new opportunities to address the ever-expanding need for natural health solutions by distributing its top-of-the-line formulas across the global market. The goal is to ensure XYMOGEN products are supplied to every distributor that recognizes the benefits of providing these innovative formulas to consumers, and has a desire to help people achieve a healthier lifestyle. XYMOGEN is currently distributing in Canada (where XYMOGEN maintains its own sales force and fulfillment center), South Korea, South Africa, China, Taiwan, Singapore, Australia, New Zealand, Mexico, Indonesia, Peru, Ecuador, Vietnam, and Ukraine – and is looking to develop markets in Iran, Saudi Arabia, Pakistan and throughout Europe. These future ventures can only be realized through strong partnerships with potential distributors who share XYMOGEN’s vision.
  • ePedigree Verification: XYMOGEN provides products only to licensed healthcare practitioners and their authorized patients. Products sold through discount Internet websites are strictly prohibited. These suppliers are not approved distributors, and XYMOGEN cannot guarantee the authenticity, potency or efficacy of products purchased through such sites. The main goal of our ePedigree initiative is to protect consumers from receiving unauthentic XYMOGEN products from unauthorized Internet sources by creating an electronic record which tracks our products as they move from the manufacturing floor to the customer. With ePedigree, we are eliminating all Internet sales of XYMOGEN-labeled formulas, resulting in XYMOGEN being the only truly exclusive source of proprietary supplements in the practitioner channel.
  • PersonaLogiX® Personalized Nutrition Program: XYMOGEN’s exclusive, professional formulas are precisely calculated to restore nutritional depletions based on the patient’s unique lifestyle, diet or drug therapies, and timed to support optimum effectiveness. Beginning with a thorough evaluation of a patient’s medical history, our proprietary system develops a detailed, individualized report from which formula recommendations are derived, and then combines the formulas into convenient AM/PM dose packs for a personal nutritional supplement kit. With our three-step approach – exact formula, exact dosing, and exact timing – we take the guesswork out of choosing and using dietary supplements to support the goal of optimal health.
  • PharmaceutiX® Medical Foods: The rising demand for natural health products has created great potential to introduce new formulas onto the market. As a company that is looking to grow and expand, the possibilities for XYMOGEN are endless, as we strive to develop formulas that can help an even larger base of the patient population. Medical foods are defined by the FDA as foods specifically formulated to provide nutrients for the management of a disease for which there is a recognized nutrient dysfunction or deficiency component. Medical foods must be used under the care and oversight of a physician, and they must meet the FDA’s rigorous safety requirements.
  • Private Label Program: Using this powerful tool, doctors and practitioners everywhere are seeing results, attributed to having personal and customized labels, doctor reference sheets and booklets for their favorite XYMOGEN formulas.
  • Custom Manufacturing: This option allows our customers to develop their own formulas, including ingredients and amounts, while XYMOGEN seeks out the very best raw materials and offers a choice of delivery methods, coating, packaging and labeling. These formulas are manufactured in XYMOGEN’s state-of-the-art facility to ensure the customer’s creation is exactly as they imagined it, if not better.
  • Contract Manufacturing: Based on the extraordinary growth of both XYMOGEN’s infrastructure and team, we are now well-positioned to fulfill orders in Contract Manufacturing, our fastest growth division. XYMOGEN has also received commitments from three of its European Biotech partners to become the exclusive manufacturer for a series of patented and proprietary ingredients.
  • Labels in Motion™: XYMOGEN’s label publishing company is an expert in the creation of digital print products. Providing label services for XYMOGEN®, PersonaLogiX®, PharmaceutiX®, private label, and custom and contract manufacturing customers, Labels in Motion also partners with brands and industries around the world to design and manufacture labels with an unbeatable quality and value.

 

Financial Outlook

XYMOGEN Sets Quarterly Record Revenues for Q2 Along with Record EBITDA in June

XYMOGEN posted record monthly EBITDA of $784K for June 2016 surpassing our previous high of $739K set in March of this year. Q2 2016 Revenues of $22.938 million also set a record for the company. Net Sales for the first six months of 2016 increased 15.3% to $45,549,825 compared to the $39,500,750 generated during the same period last year.

This follows the 2015 double-digit revenue gains for the eleventh straight year. For fiscal year 2015, net revenue grew 15.4% to $78.9 million vs. $68.4 million in 2014. Audited EBITDA is $3.15 million for 2015 vs. $3.67 million for 2014 as higher than expected spending on legal, inventory write-offs and new initiatives contributed to this lower than expected profit level. The share price increased 15.3% to $96.54 from the $83.72 value on December 31, 2014.

The Management Team is more excited than ever with high expectations for the remainder of 2016 and 2017. A new HP Digital Press, new MedPax machine, new high-speed capsule and tablet machines and an additional packaging line will all increase our capability and manufacturing capacity going forward. These additions and improvements will enable us to do more contract manufacturing business, improve manufacturing efficiency and drive down operating costs.

Our updated PPM is now available to investors and details many of the initiatives that are expected to substantially contribute to revenues at steadily increasing rates over at least the next 18 months. The elimination of online sales through our ePedigree track & trace technology, adding Reps and introducing new formulas to PharmaceutiX (our Medical Foods brand), offering Private Label in Canada and increasing the number of International Distributors are all well under way or will be implemented throughout the year.

For fiscal year 2016, XYMOGEN's Finance Team is forecasting ranges for our revenue, EBITDA and Share Price that will be dependent on the timing with which our initiatives can be implemented. We are projecting revenue to grow 18% - 25% equating to $93.2 - $99 million with a record EBITDA of $4.2 - $5.8 million. We are also forecasting that the share price will increase another 6% - 13% to $109 - $117 by year-end from the current Q2 level of $103.26.

Per covenants with Bank of America and TD Bank relating to $13.64 million of building and equipment financing, Vestal & Wiler CPA's completed the full 2015 audit on April 6, 2016.

The forecast will be updated monthly with the revised estimates included in the quarterly Investor Newsletter and on the website. Detailed financial statements and a copy of the completed 2015 audit will be made available to investors upon request.

 

XYMOGEN SHAREHOLDERS

Shareholders who would like to request a detailed report of their current XYMOGEN stock holdings, a copy of XYMOGEN’s most current audited financial statements and/or Private Placement Memorandum (PPM) may email Kim.Johnson@XYMOGEN.com.


 

Investing in XYMOGEN

Should you wish to consider an investment at this time, at the 2016 Q2 price of $103.26, please email Kim.Johnson@XYMOGEN.com to request an investor information packet and Intent-to-Buy. Please note that this offering price expires on October 14, 2016 when the new share valuation for 2016 Q3 posts to our website. In order to preserve this pricing, your completed Intent-to-Buy must be received no later than October 14, 2016. This Intent is non-binding, and allows two weeks after receipt to fund the investment at the $103.26 offering price. IRA transfers and roll-overs generally require additional time to fund and, thus, the funding deadline will be extended; however, your Intent must still be received by October 14, 2016.

Disclosure:This information contains forward-looking statements, including those related to revenue, non-operating expenses, tax rates, earnings, and our ability to continue to align our business to successfully respond to opportunities and changes in our industry. The financial information set forth herein reflects estimates based on information available at this time.

Management Team

Brian Blackburn

Brian Blackburn

CEO, Founder of XYMOGEN

As CEO of XYMOGEN, Brian guides the company's growth and success in close cooperation with executive management and the board of directors. He began his career in the physician based, nutritional sciences industry more than 25 years ago, focusing primarily in the areas of research & development and natural ingredient sourcing. In 2003 he researched, developed and launched the XYMOGEN line of professional formulas. Prior to launching XYMOGEN, Brian was president of the most successful independent distributorship for the largest company in the practitioner-based nutrition market. Building on his background in biochemistry and post-graduate education, Brian has developed functional medicine continuing education programs that have been presented extensively to thousands of physicians across the U.S. since 1995. He received his bachelor of science in biochemistry from John Carroll University.


Stephanie Blackburn

Stephanie Blackburn

Chief Operating Officer

As Chief Operations Officer, Stephanie is responsible for overseeing the management of all of XYMOGEN’s operational areas, including manufacturing, inventory, fulfillment, finance, human resources, marketing, and customer service. She attended the University of Maryland; after which, she began her career in health care operations by ensuring the personnel and budget needs of some of the nation’s top medical research institutions were met. In 1990, Stephanie and Brian moved to Florida to begin a two-person distributorship out of their garage, which eventually grew into a major nutraceutical manufacturer that now employs more than 350 employees. For more than 25 years, Stephanie’s role within the company has remained very hands-on, and she still oversees all personnel decisions, personally signs every check, and actively works to instill XYMOGEN’s core values and culture in all employees.


Mike Mahoney

Mike Mahoney

Senior Vice President

Mike oversees the development and execution of XYMOGEN®'s Sales and Strategic Marketing initiatives and works closely with the company's well tenured consultant sales team. Mike brings a wealth of industry knowledge that encompasses 20 years of experience in the fields of nutrition and natural medicine. He has cultivated relationships at high levels in a large number of medical offices, hospitals and institutions across the country. His contacts and highly regarded reputation in the industry are well known as he is a sought after speaker and consultant. He received academic and athletic scholarships to Fort Hays State University where he received his Bachelor of Science degree in Exercise Physiology.


Jesse Cothran

Jesse Cothran

Vice President, International and Regulatory Affairs

Jesse Cothran has been working in the nutraceutical industry for 15 years and comes with a wealth of experience in international business development, operations, quality and regulatory. His experience and hard work have helped more than two dozen companies, some as large as billion dollar enterprises, establish and grow key markets around the world in Asia, Southeast Asia, Europe, Latin America, and other markets. Jesse joined XYMOGEN in June 2012 and as the Executive Vice President of International and Regulatory he has been an integral part in securing GMP certification for their manufacturing facility, increasing international sales, improving operations and manufacturing processes, and helping the international markets expand their product portfolios and business operations.


Daniel Gulick

Daniel Gulick

Vice President, Custom Manufacturing

Daniel Gulick has 19 years of experience working in manufacturing and cGMP compliance. He oversees the critical steps involved in the manufacture of nutraceuticals to assure their stability and efficacy. Daniel earned a Bachelor of Science degree in biology from Arizona State University in 1993. He continues to provide expert judgment to ensure the safety and quality of all formulas manufactured at our facility.

Careers

XYMOGEN is a leader in the dietary supplement industry, with nearly a quarter century of experience in providing exceptional quality formulas and educational events to licensed healthcare practitioners in the United States and internationally.

Job Openings


XYMOGEN® LIFE

We are a “People-First” organization that prides itself on the personal relationships we nurture every day, both at the office and in the field. Our team spirit and drive for excellence have propelled XYMOGEN ever forward: From humble beginnings, we are now one of the fastest-growing and most respected private companies in America. Whatever your specialty—research, face-to-face interactions with practitioners, manufacturing, marketing, quality control, or customer service—we are looking for your unique slice of brilliance. Our motto is “The Journey Is the Reward,” and what a fulfilling and exciting journey it’s been so far! Join our team as we continue on this dynamic journey and help us create a healthier, more-informed population, one person at a time.


Global Headquarters
Contact Us

Send

© 2015. XYMOGEN®. All right reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.